
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
Published on December 26, 2024
entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale
